TENX revenueQ3 2026$0
TENX revenue was $0 in fiscal Q3 2026 (ended Sep 30, 2026), compared with $0 a year earlier. For the full fiscal 2025 it was $0, compared with $0 in fiscal 2024.
Tenax Therapeutics Inc. (TENX) financials
For the twelve months ended Sep 30, 2026, Tenax Therapeutics Inc. reported $0 of revenue and -$65.76M of net income.
- Revenue, TTM
- $0
- Net income, TTM
- -$65.76M
- EPS, diluted, TTM
- -$1.40
- Cash
- $113.70M
- Market cap
- $81.1M
FY2016FY2025
FY2016FY2025
FY2016FY2022
TENX revenue and earnings growth
TENX net incomeQ3 2026-$16.70M
TENX net income was -$16.70M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$15.80M a year earlier. For the full fiscal 2025 it was -$52.60M, compared with -$17.60M in fiscal 2024.
TENX EPSQ3 2026-$0.31
TENX diluted EPS was -$0.31 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.40 a year earlier. For the full fiscal 2025 it was -$1.34.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | - | - | - | - | - | - | - | $0 |
| Cost of revenue | - | - | - | - | - | - | - | - | - | $0 |
| Gross profit | - | - | - | - | - | - | - | - | - | $0 |
| Research and development | $32.67M | $12.71M | $3.23M | $5.38M | $25.15M | $4.56M | $3.47M | $1.24M | $3.53M | $13.14M |
| Selling, general and admin | $23.71M | $6.79M | $5.00M | $5.68M | $7.58M | $5.31M | $5.08M | $5.65M | $5.68M | $6.25M |
| Operating income | -$56.38M | -$19.49M | -$8.23M | $11.05M | -$32.73M | $9.87M | -$8.56M | -$6.89M | -$9.21M | -$52.65M |
| Interest expense | $0 | $23.0K | $24.0K | $4.4K | $949 | $1.6K | $0 | - | - | $0 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$7.96M |
| Net income | -$52.60M | -$17.60M | -$7.71M | $11.05M | -$32.47M | -$9.85M | -$8.39M | -$14.14M | -$8.84M | -$43.92M |
| EPS, basic | -$1.34 | -$1.15 | -$31.04 | - | -$1.58 | -$0.95 | -$1.35 | -$9.04 | -$6.27 | -$31.24 |
| EPS, diluted | -$1.34 | -$1.15 | -$31.04 | - | -$1.58 | -$0.95 | -$1.35 | -$9.04 | -$6.27 | -$31.24 |
| Diluted shares | 39.2M | 15.3M | 248,447 | - | 20.6M | 10.4M | 6.2M | 1.6M | 1.4M | 1.4M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $97.56M | $94.85M | $9.79M | $2.12M | $5.58M | $6.25M | $4.91M | $12.37M | $1.60M | $10.00M |
| Short-term investments | - | - | - | - | $0 | $462.7K | $493.9K | $494.6K | $6.12M | $3.28M |
| Receivables | - | - | - | - | - | - | - | $0 | $50.2K | $72.6K |
| Current assets | $104.23M | $96.69M | $11.68M | $3.21M | $5.69M | $6.80M | $6.18M | $13.32M | $8.06M | $13.63M |
| Goodwill | - | - | - | - | - | - | - | - | - | $0 |
| Total assets | $104.23M | $96.69M | $11.69M | $3.40M | $5.99M | $6.87M | $6.37M | $13.34M | $9.89M | $23.34M |
| Current liabilities | $7.16M | $4.69M | $3.59M | $1.85M | $1.56M | $2.12M | $2.53M | $1.57M | $1.01M | $6.20M |
| Total debt | - | - | - | $624.3K | $0 | $124.2K | - | - | - | - |
| Total liabilities | $7.16M | $4.69M | $3.59M | $1.91M | $1.75M | $2.24M | $2.59M | $1.57M | $1.01M | $6.20M |
| Shareholders' equity | $97.07M | $91.99M | $8.10M | $1.49M | $4.24M | $4.63M | $3.77M | $11.77M | $8.88M | $17.14M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$35.80M | -$14.81M | -$5.90M | -$11.39M | -$10.86M | -$9.27M | -$7.56M | -$5.50M | -$12.14M | -$15.87M |
| Capital expenditures | - | - | - | $2.3K | $5.3K | $3.5K | $3.6K | $7.6K | $4.5K | $2.9K |
| Free cash flow | - | - | - | -$11.39M | -$10.86M | -$9.28M | -$7.56M | -$5.51M | -$12.15M | -$15.87M |
| Investing cash flow | - | $0 | $3.0K | -$2.3K | $452.6K | $20.1K | -$1.7K | $7.35M | $3.75M | $22.21M |
| Financing cash flow | $38.51M | $99.87M | $13.57M | $7.93M | $9.74M | $10.60M | $96.5K | $8.91M | $0 | $0 |
| Stock-based compensation | $19.16M | $1.13M | $191.0K | - | - | - | $0 | $190.1K | $79.6K | $1.1K |
| Depreciation and amortization | - | $0 | $8.0K | $5.1K | $4.1K | $4.1K | $5.0K | $9.0K | $13.6K | $19.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | - | - | - | -100.0% |
| Return on equity | -54.2% | -19.1% | -95.2% | 740.0% | -765.1% | -213.0% | -222.5% | -120.2% | -99.5% | -256.3% |
| Return on assets | -50.5% | -18.2% | -66.0% | 324.5% | -541.9% | -143.4% | -131.9% | -106.0% | -89.4% | -188.2% |
| Current ratio | 14.56 | 20.60 | 3.26 | 1.74 | 3.64 | 3.21 | 2.44 | 8.51 | 7.99 | 2.20 |
| Debt to equity | - | - | - | 0.42 | 0.00 | 0.03 | - | - | - | - |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | - | - | - | - | - |
| Research and development | $12.07M | $12.85M | $11.54M | $10.54M | $10.33M | $6.12M | $5.68M | $4.59M | $3.11M | $2.33M | $2.68M | $1.70M |
| Selling, general and admin | $5.66M | $5.93M | $5.03M | $5.91M | $6.48M | $5.67M | $5.66M | $2.70M | $1.51M | $1.34M | $1.23M | $1.64M |
| Operating income | -$17.73M | -$18.78M | -$16.57M | -$16.45M | -$16.81M | -$11.79M | -$11.34M | -$7.29M | -$4.62M | -$3.67M | -$3.91M | -$13.13M |
| Interest expense | - | - | - | - | - | - | - | -$1.0K | $7.0K | $9.0K | $8.0K | $2.2K |
| Net income | -$16.70M | -$17.80M | -$15.72M | -$15.54M | -$15.80M | -$10.85M | -$10.41M | -$6.27M | -$3.96M | -$3.58M | -$3.80M | -$12.20M |
| EPS, basic | -$0.31 | -$0.35 | -$0.35 | -$0.39 | -$0.40 | -$0.27 | -$0.28 | - | -$0.19 | -$1.83 | -$3.12 | - |
| EPS, diluted | -$0.31 | -$0.35 | -$0.35 | -$0.39 | -$0.40 | -$0.27 | -$0.28 | - | -$0.19 | -$1.83 | -$3.12 | - |
| Diluted shares | 53.5M | 50.9M | 45.2M | - | 39.7M | 39.6M | 36.6M | - | 21.2M | 2.0M | 1.2M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $113.70M | $118.00M | $118.80M | $97.56M | $99.37M | $105.46M | $111.45M | $94.85M | $98.31M | $9.38M | $12.55M | $9.79M |
| Current assets | $117.01M | $121.66M | $123.18M | $104.23M | $102.81M | $105.86M | $112.06M | $96.69M | $99.78M | $10.62M | $14.46M | $11.68M |
| Total assets | $117.01M | $121.66M | $123.18M | $104.23M | $102.81M | $105.86M | $112.06M | $96.69M | $99.78M | $10.62M | $14.46M | $11.69M |
| Current liabilities | $8.36M | $8.07M | $8.49M | $7.16M | $6.60M | $2.53M | $2.77M | $4.69M | $2.56M | $1.74M | $2.03M | $3.59M |
| Total liabilities | $8.36M | $8.07M | $8.49M | $7.16M | $6.60M | $2.53M | $2.77M | $4.69M | $2.56M | $1.74M | $2.03M | $3.59M |
| Shareholders' equity | $108.66M | $113.59M | $114.69M | $97.07M | $96.21M | $103.33M | $109.29M | $91.99M | $97.22M | $8.88M | $12.43M | $8.10M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.48M | -$14.15M | -$9.31M | -$13.41M | -$9.15M | -$6.26M | -$6.97M | -$3.53M | -$3.09M | -$3.03M | -$5.17M | -$1.18M |
| Investing cash flow | - | - | - | - | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $157 |
| Financing cash flow | $8.23M | $13.37M | $30.50M | $11.61M | $3.06M | $278.0K | $23.56M | $67.0K | $92.01M | -$134.0K | $7.92M | -$174.6K |
| Stock-based compensation | $3.54M | $3.33M | $2.84M | $4.79M | $5.62M | $4.61M | $4.14M | $970.0K | $14.0K | $22.0K | $119.0K | - |
| Depreciation and amortization | - | - | - | - | - | - | - | $0 | $0 | $0 | $0 | $5.1K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 14.01 | 15.07 | 14.52 | 14.56 | 15.58 | 41.89 | 40.48 | 20.60 | 38.95 | 6.10 | 7.12 | 3.26 |
Source: XBRL data Tenax Therapeutics Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported Jun 26, 2013; 1-for-20, first reported Apr 2, 2018.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
TENX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| TENX | $0 | - | -$65.76M | - | $81.1M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
TENX FAQ
6 questionsWhat is TENX revenue?
Tenax Therapeutics Inc. (TENX) reported $0 of revenue for the twelve months ended Sep 30, 2026. Revenue for fiscal 2025 was $0.Is TENX profitable?
No. Tenax Therapeutics Inc. reported a net loss of $65.76M for the twelve months ended Sep 30, 2026.How much cash and debt does TENX have?
Tenax Therapeutics Inc. reported $113.70M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is TENX earnings per share?
Diluted earnings per share were -$1.40 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did TENX last report financial results?
The latest statements here come from Tenax Therapeutics Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.Where does this TENX financial data come from?
Quantisnow builds these statements from the structured XBRL data Tenax Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.